咳嗽是一种常见的呼吸道症状,感冒、过敏等因素都可能引发,大部分人不会过多在意。但是,如果咳嗽持 续数月甚至数年,还伴随活动后呼吸困难,就需要警惕一种隐匿且可能持续进展的肺部疾病——间质性肺 病。 山东第一医科大学第一附属医院(山东省千佛山医院)呼吸与危重症医学科副主任兼一病区主任季翔提醒, 这类疾病病因复杂、早期症状易被忽视,约30%-40%患者可能进展为肺纤维化,严重影响呼吸功能,早发 现、早干预是改善预后的关键。 记者 秦聪聪 济南报道 间质性肺病本质 是肺部"墙体"出了问题 "如果把肺部的肺泡比作一个个'房间',肺泡本身就是肺实质,而房间之间的'墙体',以及墙里的血管、淋巴 管、神经等结构,就是肺间质。"季翔介绍,间质性肺病,就是"墙体"发生了炎症或病变。 和肺炎、肺癌相比,三者的核心区别在于发病位置和疾病性质不同:肺炎多是"房间"里出现了感染,由细 菌、病毒等病原体引发,通过抗感染治疗往往能取得较好效果；肺癌是"房间"或"墙体"上长出了恶性肿 瘤；而间质性肺病是"墙体"本身发炎、变硬,甚至逐渐纤维化,它不是感染性疾病,也不是恶性肿瘤,但治疗 难度不小,且病情可能持续进展。 如果发展到肺纤维化阶段,肺部 ...

Core Viewpoint - The study reveals that cancer cell-secreted DDAH1 protein accelerates lung aging by promoting the accumulation of citrulline, providing new insights for the treatment and diagnosis of tumors through the inhibition of aging lung fibroblasts [3][6]. Group 1: Research Findings - The research indicates that DDAH1 protein secreted by cancer cells induces the TGF-β1/Smad3 signaling pathway, leading to lung fibrosis and aging [3][6]. - The study identifies that increased levels of citrulline inhibit PAD4-mediated citrullination of TGF-β1, thereby activating the TGF-β1/Smad3 signaling pathway in lung fibroblasts [4][6]. - The use of DDAH1 inhibitors has been shown to effectively reduce lung fibrosis and delay lung aging [5][6]. Group 2: Methodology - The research utilized single-cell sequencing and gene knockout mouse experiments to confirm the mechanisms involved in the accumulation of citrulline and its effects on lung aging [4]. - The study highlights the role of vesicle sorting proteins in packaging DDAH1 into late endosomes [4]. Group 3: Implications - The findings suggest a potential therapeutic approach targeting DDAH1 to mitigate lung aging and fibrosis, which could lead to advancements in cancer treatment strategies [6].

Core Insights - Guangdong Hengrui Medicine Co., Ltd. has initiated a Phase I clinical trial for HRS-9813, a drug aimed at treating pulmonary fibrosis, with the trial registered under CTR20254413 and publicly announced on November 6, 2025 [1] Group 1: Clinical Trial Details - The primary objective of the trial is to evaluate the pharmacokinetic interactions of HRS-9813 capsules with pirfenidone and nintedanib in healthy subjects [1] - Secondary objectives include assessing the safety and tolerability of the drugs when used alone and in combination, as well as exploring the metabolic characteristics of HRS-9813 in healthy subjects [1] - The trial is currently ongoing with a target enrollment of 20 participants, although recruitment has not yet started [2] Group 2: Drug Information - HRS-9813 is a chemical drug indicated for pulmonary fibrosis, a condition characterized by lung tissue damage leading to scarring, with symptoms including dry cough and progressive shortness of breath [1] - High-resolution CT scans can assist in the diagnosis of pulmonary fibrosis [1]